Field Trip FT-104 Phase IIa Trial

Field Trip Health have developed a novel psychedelic compound FT-104. FT-104 is a synthetic serotonin-2A (5HT2A) agonist whose active component has serotonin-2A potency similar to psilocybin however, FT-104 is expected to produce a reliably shorter duration of psychoactivity (2-3 hours) than psilocybin, and has high bioavailability after administration.

Field Trip are conducting preclinical activities with FT-104 which will enable commencement of Phase I trials in early 2022.

This Phase IIa study will build on the results of Phase Is trials and assess the effectiveness of FT-104 against placebo for a particular indication in patients with the disease or condition under study, including narrowing the optimal dose, the potential utility, and common short-term side effects of the molecule.

Topic Healthy Subjects Treatment-Resistant Depression Postpartum Depression
Compound Psilocybin
Country United States of America
Visit trial
Status Planned
Results Published
Start date 01 January 1970
End date 01 January 1970
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



Trial Number

Sponsors & Collaborators

Field Trip
Field Trip is a company that offers psychedelics therapies. It has several locations (US/CA) that provides ketamine-assisted therapy. It has raised $19.5M in Series A & B funding rounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.